| scholarly article | Q13442814 |
| P50 | author | Marcela F. Pasetti | Q56380831 |
| David I Bernstein | Q107723691 | ||
| Sharon E Frey | Q109938704 | ||
| Samer S. El-Kamary | Q117264856 | ||
| P2093 | author name string | Charles Richardson | |
| John J Treanor | |||
| Marcelo B Sztein | |||
| Paul M Mendelman | |||
| Jennifer Ferreira | |||
| Wilbur H Chen | |||
| Carol O Tacket | |||
| Richard Sublett | |||
| Robert F Bargatze | |||
| P2860 | cites work | Norwalk virus shedding after experimental human infection | Q22305638 |
| Cellular and humoral immunity following Snow Mountain virus challenge | Q24556676 | ||
| Human susceptibility and resistance to Norwalk virus infection | Q28190653 | ||
| Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial | Q28236008 | ||
| Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences | Q28276626 | ||
| Virus-like particles: a new family of delivery systems | Q30817169 | ||
| Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses | Q33846577 | ||
| Norwalk virus vaccines: challenges and progress | Q33914464 | ||
| Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans | Q34003433 | ||
| Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection | Q34007563 | ||
| Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice | Q34069717 | ||
| Papillomavirus-like particle vaccines. | Q34131267 | ||
| Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed | Q34194667 | ||
| Chitosan as a novel nasal delivery system for vaccines | Q34343257 | ||
| Norwalk virus infection and disease is associated with ABO histo-blood group type | Q34523042 | ||
| Systematic literature review of role of noroviruses in sporadic gastroenteritis | Q34804404 | ||
| Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties | Q36209689 | ||
| Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. | Q36474608 | ||
| Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein | Q36685153 | ||
| Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant | Q37109519 | ||
| Maturation and trafficking markers on rotavirus-specific B cells during acute infection and convalescence in children | Q40163191 | ||
| Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. | Q40181308 | ||
| Norwalk virus infection among Desert Storm troops | Q44063202 | ||
| Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers | Q45711236 | ||
| Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes | Q45741675 | ||
| Recombinant Norwalk virus-like particles given orally to volunteers: phase I study | Q45748767 | ||
| Norwalk virus infection of volunteers: new insights based on improved assays | Q45781491 | ||
| Epidemiology of Norwalk virus during an outbreak of acute gastroenteritis aboard a US aircraft carrier | Q45786276 | ||
| Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined | Q46550913 | ||
| Outbreak management and implications of a nosocomial norovirus outbreak. | Q50670624 | ||
| Structural studies of recombinant Norwalk capsids. | Q52578907 | ||
| Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. | Q55043303 | ||
| Molecular Epidemiology of “Norwalk‐like Viruses” in Outbreaks of Gastroenteritis in the United States | Q57661865 | ||
| Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04 | Q61617993 | ||
| Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland | Q76383446 | ||
| Rational design of nasal vaccines | Q80439850 | ||
| Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 | ||
| Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration | Q81611400 | ||
| Effective nasal influenza vaccine delivery using chitosan | Q81785770 | ||
| Norovirus gastroenteritis | Q84800851 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| vaccine | Q134808 | ||
| Norwalk virus | Q562082 | ||
| P304 | page(s) | 1649-1658 | |
| P577 | publication date | 2010-10-27 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues | |
| P478 | volume | 202 |
| Q38001080 | "IDEAL" vaccines for resource poor settings |
| Q45362011 | A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles |
| Q34564412 | A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. |
| Q40107672 | A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice |
| Q34685874 | A polymer/oil based nanovaccine as a single-dose immunization approach |
| Q47961163 | An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery |
| Q38285854 | Antigen delivery by virus-like particles for immunotherapeutic vaccination. |
| Q33654573 | B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine |
| Q44197060 | Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography |
| Q92665377 | Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice |
| Q38019583 | Chitosan-based delivery systems for mucosal vaccines |
| Q38566314 | Chitosan-based mucosal adjuvants: Sunrise on the ocean |
| Q38254989 | Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation. |
| Q34033764 | Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines |
| Q38122934 | Chitosans for delivery of nucleic acids. |
| Q36012177 | Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study |
| Q37679720 | Comparative evaluation of recombinant protein production in different biofactories: the green perspective |
| Q36414470 | Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication |
| Q26775082 | Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection |
| Q38618258 | Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems |
| Q42421045 | Diverse phosphorylation patterns of B cell receptor-associated signaling in naïve and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell level |
| Q35687728 | Epidemiology and Genetic Characterization of Noroviruses among Adults in an Endemic Setting, Peruvian Amazon Basin, 2004-2011. |
| Q34385139 | Epidemiology of human noroviruses and updates on vaccine development |
| Q41740579 | Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial. |
| Q27302049 | Experimental inoculation of juvenile rhesus macaques with primate enteric caliciviruses |
| Q37603557 | Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination |
| Q35665784 | Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity |
| Q36181393 | Global age distribution of pediatric norovirus cases |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q57093839 | Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses |
| Q40817517 | Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface |
| Q24810360 | Immunogenetic mechanisms driving norovirus GII.4 antigenic variation |
| Q35983587 | Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations |
| Q36017750 | Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration |
| Q36052875 | Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein |
| Q28972559 | Immunology of Gut Mucosal Vaccines |
| Q34059409 | Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs |
| Q35112676 | Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine |
| Q58556437 | Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine |
| Q47584590 | Intranasal immunization with dry powder vaccines |
| Q36017715 | Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans |
| Q37109677 | Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. |
| Q38869777 | Methods for ascertaining norovirus disease burdens. |
| Q88752692 | More robust gut immune responses induced by combining intranasal and sublingual routes for prime-boost immunization |
| Q92859918 | Mouse Norovirus Infection Arrests Host Cell Translation Uncoupled from the Stress Granule-PKR-eIF2α Axis |
| Q56877862 | Mouse Norovirus infection reduces the surface expression of MHC class I proteins and inhibits CD8+ T cell recognition and activation |
| Q36756413 | Mucosal and Cellular Immune Responses to Norwalk Virus |
| Q37885850 | Multidimensional methods for the formulation of biopharmaceuticals and vaccines. |
| Q36155501 | Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens |
| Q62391112 | Nasal Dry Powder Vaccine Delivery Technology |
| Q57169065 | Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis |
| Q34059360 | Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice |
| Q52602778 | Noninvasive vaccination against infectious diseases. |
| Q26864280 | Norovirus |
| Q34702360 | Norovirus P particle efficiently elicits innate, humoral and cellular immunity |
| Q36445296 | Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus |
| Q36201314 | Norovirus and medically attended gastroenteritis in U.S. children |
| Q28083087 | Norovirus immunology: Of mice and mechanisms |
| Q41743964 | Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults |
| Q37144052 | Norovirus vaccine against experimental human Norwalk Virus illness |
| Q37133116 | Norovirus vaccine development: next steps |
| Q36275589 | Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives |
| Q38698429 | Norovirus vaccines under development |
| Q37135476 | Norovirus vaccines: Correlates of protection, challenges and limitations |
| Q38081967 | Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis |
| Q38217316 | Norovirus: targets and tools in antiviral drug discovery |
| Q38322750 | Noroviruses: epidemiology, immunity and prospects for prevention |
| Q91862911 | Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen |
| Q44939276 | Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines |
| Q52648767 | PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. |
| Q54230568 | Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice. |
| Q42247731 | Pediatric norovirus infection |
| Q36257975 | Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice |
| Q57163766 | Progress on norovirus vaccine research: public health considerations and future directions |
| Q38557262 | Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations |
| Q40102851 | Prospects and Challenges in the Development of a Norovirus Vaccine |
| Q40309267 | Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice |
| Q38029250 | Recent progress in mucosal vaccine development: potential and limitations |
| Q52720313 | Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken. |
| Q38420174 | Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine |
| Q47579651 | Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial |
| Q84592118 | Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine |
| Q64376875 | Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial |
| Q35739052 | Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q30239859 | Structure(s), function(s), and inhibition of the RNA-dependent RNA polymerase of noroviruses |
| Q34290717 | TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines |
| Q37896347 | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases |
| Q40485965 | Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis of mass vaccination options |
| Q64947514 | The Antigenic Topology of Norovirus as Defined by B and T Cell Epitope Mapping: Implications for Universal Vaccines and Therapeutics. |
| Q33719999 | The dynamics of GII.4 Norovirus in Ho Chi Minh City, Vietnam |
| Q30404699 | The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine |
| Q36455283 | The potential economic value of a human norovirus vaccine for the United States |
| Q33678125 | The state of norovirus vaccines |
| Q40044140 | Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future |
| Q89187655 | Toxicology study for magnetic injection of prednisolone into the rat cochlea |
| Q26799737 | Tropical and travel-associated norovirus: current concepts |
| Q33578075 | Vaccine against norovirus |
| Q27004488 | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae |
| Q30249025 | Virus like particle-based vaccines against emerging infectious disease viruses |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
Search more.